ZYDUS LIFESCIENCES
Quarterly Results Analysis [Dec2023]
ZYDUS LIFESCIENCES Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹4,505 Cr | ₹4,369 Cr | ₹5,140 Cr | ₹5,011 Cr | ₹4,257 Cr | ₹4,006 Cr | ₹3,964 Cr | ₹3,806 Cr |
Expenses | ₹3,423 Cr | ₹3,305 Cr | ₹3,634 Cr | ₹3,755 Cr | ₹3,406 Cr | ₹3,319 Cr | ₹3,240 Cr | ₹3,088 Cr |
Operating Income | ₹1,082 Cr | ₹1,064 Cr | ₹1,505 Cr | ₹1,256 Cr | ₹851 Cr | ₹686 Cr | ₹725 Cr | ₹718 Cr |
Other Income | ₹58 Cr | ₹136 Cr | ₹36 Cr | ₹38 Cr | ₹144 Cr | ₹174 Cr | ₹174 Cr | ₹79 Cr |
Interest | ₹20 Cr | ₹9 Cr | ₹18 Cr | ₹28 Cr | ₹33 Cr | ₹35 Cr | ₹34 Cr | ₹39 Cr |
Depreciation | ₹195 Cr | ₹184 Cr | ₹180 Cr | ₹179 Cr | ₹182 Cr | ₹182 Cr | ₹181 Cr | ₹185 Cr |
Profit Before Tax | ₹926 Cr | ₹1,007 Cr | ₹1,329 Cr | ₹486 Cr | ₹780 Cr | ₹643 Cr | ₹681 Cr | ₹573 Cr |
Profit After Tax | ₹712 Cr | ₹781 Cr | ₹1,113 Cr | ₹349 Cr | ₹585 Cr | ₹506 Cr | ₹563 Cr | ₹464 Cr |
EPS | ₹7.80 | ₹7.91 | ₹10.74 | ₹2.93 | ₹6.16 | ₹5.16 | ₹5.06 | ₹3.88 |
Industry Peers & Returns | 1W | 1M | 1Y |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
MANKIND PHARMA | 1.3% | 7% | NA |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
LUPIN | 0.6% | 0.5% | 127.2% |
AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
ZYDUS LIFESCIENCES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 3.12 % |
Y-o-Y | 5.83 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹4,505 Cr | 3.12 | |
Sep2023 | ₹4,369 Cr | -15.00 | |
Jun2023 | ₹5,140 Cr | 2.57 | |
Mar2023 | ₹5,011 Cr | 17.70 | |
Dec2022 | ₹4,257 Cr | 6.28 | |
Sep2022 | ₹4,006 Cr | 1.04 | |
Jun2022 | ₹3,964 Cr | 4.17 | |
Mar2022 | ₹3,806 Cr | - |
ZYDUS LIFESCIENCES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 1.68 % |
Y-o-Y | 27.15 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹1,082 Cr | 1.68 | |
Sep2023 | ₹1,064 Cr | -29.32 | |
Jun2023 | ₹1,505 Cr | 19.89 | |
Mar2023 | ₹1,256 Cr | 47.58 | |
Dec2022 | ₹851 Cr | 24.01 | |
Sep2022 | ₹686 Cr | -5.31 | |
Jun2022 | ₹725 Cr | 0.96 | |
Mar2022 | ₹718 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -1.40 % |
Y-o-Y | 20.11 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 24.01% | -1.40 | |
Sep2023 | 24.35% | -16.87 | |
Jun2023 | 29.29% | 16.88 | |
Mar2023 | 25.06% | 25.36 | |
Dec2022 | 19.99% | 16.70 | |
Sep2022 | 17.13% | -6.29 | |
Jun2022 | 18.28% | -3.08 | |
Mar2022 | 18.86% | - |
ZYDUS LIFESCIENCES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -8.85 % |
Y-o-Y | 21.68 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹712 Cr | -8.85 | |
Sep2023 | ₹781 Cr | -29.85 | |
Jun2023 | ₹1,113 Cr | 219.31 | |
Mar2023 | ₹349 Cr | -40.40 | |
Dec2022 | ₹585 Cr | 15.64 | |
Sep2022 | ₹506 Cr | -10.10 | |
Jun2022 | ₹563 Cr | 21.33 | |
Mar2022 | ₹464 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -11.58 % |
Y-o-Y | 14.99 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 15.8 % | -11.58 | |
Sep2023 | 17.87 % | -17.50 | |
Jun2023 | 21.66 % | 211.21 | |
Mar2023 | 6.96 % | -49.34 | |
Dec2022 | 13.74 % | 8.79 | |
Sep2022 | 12.63 % | -10.99 | |
Jun2022 | 14.19 % | 16.50 | |
Mar2022 | 12.18 % | - |
ZYDUS LIFESCIENCES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -1.39 % |
Y-o-Y | 26.62 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹7.8 | -1.39 | |
Sep2023 | ₹7.91 | -26.35 | |
Jun2023 | ₹10.74 | 266.55 | |
Mar2023 | ₹2.93 | -52.44 | |
Dec2022 | ₹6.16 | 19.38 | |
Sep2022 | ₹5.16 | 1.98 | |
Jun2022 | ₹5.06 | 30.41 | |
Mar2022 | ₹3.88 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD